• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DNLI

    Denali Therapeutics Inc.

    Subscribe to $DNLI
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: denalitherapeutics.com

    Peers

    $FSTX

    Recent Analyst Ratings for Denali Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    2/11/2025$31.00Buy
    Deutsche Bank
    1/7/2025$31.00Outperform
    Robert W. Baird
    1/3/2025Outperform
    William Blair
    12/16/2024$37.00Hold → Buy
    Stifel
    10/10/2024Mkt Perform
    Raymond James
    10/7/2024Overweight → Neutral
    Cantor Fitzgerald
    12/13/2023$32.00Buy
    Citigroup
    11/20/2023$28.00Overweight
    JP Morgan
    See more ratings

    Denali Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Denali Therapeutics Inc.

      10-Q - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:04:50 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:03:05 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Denali Therapeutics Inc.

      DEFA14A - Denali Therapeutics Inc. (0001714899) (Filer)

      4/17/25 4:06:10 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Denali Therapeutics Inc.

      DEF 14A - Denali Therapeutics Inc. (0001714899) (Filer)

      4/17/25 4:05:24 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      4/2/25 8:02:58 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      3/5/25 5:26:35 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Denali Therapeutics Inc.

      S-8 - Denali Therapeutics Inc. (0001714899) (Filer)

      2/27/25 4:13:53 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      2/27/25 4:12:41 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3ASR filed by Denali Therapeutics Inc.

      S-3ASR - Denali Therapeutics Inc. (0001714899) (Filer)

      2/27/25 4:11:43 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Denali Therapeutics Inc.

      10-K - Denali Therapeutics Inc. (0001714899) (Filer)

      2/27/25 4:05:58 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Denali Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Denali Therapeutics Inc.

      SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 12:52:28 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 9:55:15 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/8/24 10:52:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/7/24 4:48:26 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Denali Therapeutics Inc.

      SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

      8/16/24 1:18:04 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Denali Therapeutics Inc. (Amendment)

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      2/13/24 5:02:38 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Denali Therapeutics Inc. (Amendment)

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      2/13/24 4:27:05 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Denali Therapeutics Inc. (Amendment)

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      2/12/24 7:07:55 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Denali Therapeutics Inc.

      SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

      2/8/24 10:11:32 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Denali Therapeutics Inc. (Amendment)

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      1/30/24 6:59:07 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Denali Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ho Carole sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 8% to 175,673 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:26:37 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COFO and Secretary Schuth Alexander O. sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 6% to 244,308 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:25:44 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Watts Ryan J. sold $750,955 worth of shares (36,916 units at $20.34), decreasing direct ownership by 13% to 253,071 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:24:43 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krognes Steve E. sold $69,485 worth of shares (3,339 units at $20.81), decreasing direct ownership by 11% to 25,757 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:23:57 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Watts Ryan J. was granted 54,180 shares, increasing direct ownership by 23% to 289,987 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/7/25 6:59:45 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COFO and Secretary Schuth Alexander O. was granted 54,180 shares, increasing direct ownership by 26% to 259,470 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/7/25 6:57:55 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Ho Carole was granted 54,180 shares, increasing direct ownership by 40% to 190,835 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/7/25 6:56:19 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Krognes Steve E. sold $607,500 worth of shares (30,000 units at $20.25), decreasing direct ownership by 51% to 29,096 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/3/25 4:14:23 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sato Vicki L sold $64,403 worth of shares (3,080 units at $20.91), decreasing direct ownership by 3% to 107,976 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/3/25 4:13:51 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COFO and Secretary Schuth Alexander O. exercised 6,708 shares at a strike of $5.28, increasing direct ownership by 3% to 205,290 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      12/31/24 4:18:12 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Denali Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

      Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously

      3/7/25 8:22:55 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Denali Therapeutics with a new price target

      Deutsche Bank initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $31.00

      2/11/25 7:04:19 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Denali Therapeutics with a new price target

      Robert W. Baird initiated coverage of Denali Therapeutics with a rating of Outperform and set a new price target of $31.00

      1/7/25 7:50:21 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Denali Therapeutics

      William Blair initiated coverage of Denali Therapeutics with a rating of Outperform

      1/3/25 8:03:09 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Denali Therapeutics from Hold to Buy and set a new price target of $37.00

      12/16/24 6:43:50 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Raymond James resumed coverage on Denali Therapeutics

      Raymond James resumed coverage of Denali Therapeutics with a rating of Mkt Perform

      10/10/24 8:38:30 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics downgraded by Cantor Fitzgerald

      Cantor Fitzgerald downgraded Denali Therapeutics from Overweight to Neutral

      10/7/24 7:51:03 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Citigroup initiated coverage on Denali Therapeutics with a new price target

      Citigroup initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $32.00

      12/13/23 6:55:33 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan resumed coverage on Denali Therapeutics with a new price target

      JP Morgan resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $28.00

      11/20/23 7:27:12 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Denali Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

      O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar

      4/8/24 8:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

      Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors  CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be

      1/9/24 8:44:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

      Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.

      11/27/23 7:01:00 PM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

      CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t

      10/2/23 7:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • ProFound Therapeutics Expands Leadership Team With Appointment of Klaus Urbahns as Chief Scientific Officer

      ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m

      9/25/23 7:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

      CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry.  She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy. "Partner

      9/11/23 6:30:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

      CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development. Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets inc

      8/29/23 8:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

      CAMBRIDGE, Mass., Aug. 14, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act specifically at the site of disease and nowhere else, today announced that Jason Gardner, Ph.D., has joined Flagship Pioneering as CEO-Partner, and Ampersand as Chief Executive Officer and member of its Board of Directors. Gardner brings more than two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a succ

      8/14/23 7:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cellarity Appoints Dr. Gregory J. Moore to Board of Directors

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the appointment of Gregory J. Moore, M.D., Ph.D., to the Company's Board of Directors. As the former Corporate Vice President for Microsoft, leading global health and life sciences, Dr. Moore brings extensive experience and expertise in integrating R&D, AI and machine learning, and cloud and data technologies to positively transform companies within the health and life sciences ecosystem. "Greg is an industry leader, driving technology and life sciences innovation at the intersection of medical and large-scale computation," said Stephen Berenson, Chairman of Cellar

      6/6/23 8:00:00 AM ET
      $DNLI
      $DVA
      $EVLO
      $FHTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Misc Health and Biotechnology Services
      Biotechnology: Pharmaceutical Preparations
    • Montai Health Adds Industry Leaders to its Board of Directors

      - Michael Severino, M.D. and Andreas Fibig bring decades of drug development and commercialization leadership experience to Montai Montai Health, a company unlocking the power of nature with digital technologies to treat and preempt chronic disease, today announced the appointment of Michael Severino, M.D., and Andreas Fibig to the Company's Board of Directors. Dr. Severino and Mr. Fibig bring decades of drug development and commercialization leadership experience to Montai, where their expertise and support will be critical as the company advances its artificial intelligence (AI) platform to enable the predictable discovery of breakthrough small molecules for chronic disease. "I'm thri

      5/17/23 7:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    Denali Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

      Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval for tividenofusp alfaProductive collaboration continues under START for an accelerated development and approval path for DNL126 SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has bee

      4/2/25 8:00:44 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. "In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle (ETV) programs, achieving a path to a potential accelerated approval for our lead program in MPS II," said Ryan Watts, Ph.D., CEO of Denali. "In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and a

      2/27/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

      Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behaviorLong-term safety data with median follow-up of two years, and out to more than four years, demonstrate that tividenofusp alfa was generally well tolerated Regulatory submission for accelerated approval is planned for early 2025; U.S. launch preparation is ongoing to deliver tividenofusp alfa to families with MPS II in late 2025 or early 2026 SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced the primary analysis of the Phase 1/2

      2/6/25 11:42:00 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

      SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced upcoming oral (platform) and poster presentations at the 21st Annual WORLDSymposium™, which will be held February 3-7, 2025, in San Diego, California. The oral presentation includes clinical results related to its Hunter syndrome (MPS II) investigational therapeutic, tividenofusp alfa (DNL310). Tividenofusp alfa is enabled by the Denali TransportVehicle™ platform, which is designed to effectively deliver enzyme, oligonucleotide, or antibody therapeutics to all tissues in the body, including the brain by crossing the blood-brain barrier. The presentation schedule at WORLDS

      1/30/25 8:00:00 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

      FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in early 2025Preparing for commercial launch of tividenofusp alfa for Hunter syndrome in late 2025 or early 2026Enable accelerated approval pathway for DNL126 for Sanfilippo syndrome Type A (MPS IIIA)Expand and advance portfolio of multiple TransportVehicleTM (TV) enabled programs for delivery of enzyme, oligonucleotide, and antibody therapeutics for rare and common diseases SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced key anticipated milestones for 2025 across its

      1/13/25 8:00:00 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

      SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment of individuals with Hunter syndrome (MPS II). This designation is in addition to Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation, all previously granted by the FDA for tividenofusp alfa in Hunter syndrome. Denali expects to submit a Biologics License Application (BLA) for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway. "FDA Breakthrough Therapy De

      1/8/25 8:00:00 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

      Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not met at 24 weeksOverall, DNL343 was found to be safe and well toleratedAdditional analyses, including neurofilament light (NfL) and other fluid biomarkers, prespecified sub-group analyses and analyses from the active treatment extension period are expected later in 2025 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic lateral scle

      1/6/25 4:30:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

      SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson's disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson's disease by targeting underlying lysosomal dysfunction implicated in this disease. The Phase 2a study is intended to evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson's disease and LRR

      12/5/24 8:00:00 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

      Recent successful meeting with the FDA provides path to file for accelerated approval and subsequent conversion to full approvalPlan to submit biologics license application (BLA) early in 2025 under the accelerated approval pathwayNew Phase 1/2 data will be presented this week at SSIEM 2024 demonstrating robust and durable biomarker responses and positive effects on clinical outcomes SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologi

      9/3/24 8:00:27 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care